James N. Topper, Director at NewAmsterdam Pharma Co N.V. (NAMS), bought 471 shares at $23.98 ($11K) on 2025-08-11, disclosed to the SEC on 2025-08-13.
Open-market purchase of $11k NAMS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| NAMS | BUY | 2025-06-26 | $69K | — | Filing → |
| NAMS | BUY | 2025-06-18 | $167K | — | Filing → |
| PHAT | BUY | 2025-05-23 | $15K | — | Filing → |